Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction of ZELBORAF 240MG TABLET:
Vemurafenib, marketed under the brand name Zelboraf, is a medication used in the treatment of certain types of cancer. It falls under the class of drugs known as kinase inhibitors, specifically targeting cancer cells with specific genetic mutations. Vemurafenib was initially approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of metastatic melanoma, a type of skin cancer, with a particular genetic mutation known as BRAF V600E.
Mechanism of Action of ZELBORAF 240MG TABLET:
The mechanism of action of Zelboraf (Vemurafenib) revolves around its ability to inhibit a specific protein called BRAF kinase. In approximately 50% of melanoma cases, there exists a mutation in the BRAF gene, leading to the production of an abnormal version of the BRAF protein known as V600E. This abnormal protein remains constitutively active, continuously sending signals to promote uncontrolled cell growth and division, thus contributing to cancer development and progression.
Vemurafenib is designed to selectively bind to the mutant BRAF protein, inhibiting its activity. Consequently, the drug disrupts the signaling pathways that drive cancer cell growth, resulting in reduced tumor growth and, in some instances, tumor shrinkage.
Uses of ZELBORAF 240MG TABLET:
The primary use of vemurafenib (Zelboraf) is for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation. Before its introduction, metastatic melanoma presented limited treatment options and a poor prognosis. Vemurafenib has exhibited significant clinical benefits in patients with this specific genetic mutation, leading to its approval for this indication.
Benefits of ZELBORAF 240MG TABLET:
Improved Survival:
Vemurafenib has demonstrated increased overall survival and progression-free survival in patients with BRAF V600E mutant metastatic melanoma compared to conventional chemotherapy.